Today: 11 June 2026
Intel stock dips in year-end trade as Nvidia’s $5 billion stake stays in focus for INTC
31 December 2025
2 mins read

Intel stock dips in year-end trade as Nvidia’s $5 billion stake stays in focus for INTC

NEW YORK, December 31, 2025, 5:02 PM ET — After-hours

  • Intel shares fell about 1% in Wednesday’s regular session and were little changed in after-hours trading.
  • Investors continue to weigh Nvidia’s newly disclosed $5 billion equity purchase in Intel via a private placement.
  • Focus turns to early-January macro data and Intel’s next quarterly update as 2026 trading begins.

Intel Corp (INTC) shares fell about 1.0% in Wednesday’s regular session to $36.90 and were little changed in after-hours trading. The stock ranged from $36.84 to $38.01 on the day, with volume around 51 million shares.

The move tracked a tech-led dip that pulled the S&P 500 down 0.73% and the Nasdaq off 0.76% in holiday-thin trading, Reuters reported. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

For Intel, the year-end pullback matters because the stock has become tightly linked to sentiment on big, capital-heavy turnarounds in semiconductors. Investors have been weighing how quickly Intel can stabilize finances while spending to expand manufacturing capacity.

Nvidia has purchased Intel shares worth $5 billion, Intel said in a filing on Monday, completing a transaction announced in September. Nvidia agreed to pay $23.28 per share for more than 214.7 million Intel shares in a private placement — a sale directly to an investor rather than in a public offering — after U.S. antitrust agencies cleared the investment earlier in December, Reuters reported. Reuters

At Wednesday’s close, Intel traded about 58% above Nvidia’s $23.28 entry price. On that basis, Nvidia’s stake would be worth roughly $7.9 billion, keeping the focus on whether Intel can translate new capital into operational progress.

Macro data also stayed on traders’ screens. U.S. weekly jobless claims fell to 199,000 for the week ended Dec. 27, below economists’ forecast of 220,000, a report on Wednesday showed. Reuters

Rate expectations matter for Intel because chip stocks often move with broader tech valuations, which can be sensitive to changes in borrowing costs. A lower-rate outlook typically supports growth multiples, while higher-for-longer rates can compress them.

Competitive pressure remains a backdrop. Intel faces Advanced Micro Devices in PC and server processors, while Nvidia dominates the market for AI accelerators that power many data-center builds.

Investors will be watching for any follow-up disclosures on how the Nvidia stake translates into deeper commercial or technology collaboration between the long-time rivals. They will also look for signals on whether Intel can sustain momentum as it invests in factories and advanced manufacturing capabilities.

The next major macro waypoint is the U.S. December employment report, scheduled for Jan. 9, according to the Bureau of Labor Statistics. Bureau of Labor Statistics

Company-specific attention is on Intel’s next earnings update, when executives are likely to face questions on cash flow and spending plans tied to its manufacturing push. Intel is expected to report results on Jan. 29, according to Nasdaq’s earnings calendar. Nasdaq

Technically, traders will also watch whether the stock holds above Wednesday’s intraday low near $36.84 as liquidity returns after the holiday week. A slip below that area would put the $35 level in focus early in 2026.

For now, Intel heads into the new year with a fresh $5 billion infusion from Nvidia and a market still dominated by AI-linked winners. The first sessions of 2026 will test whether Wednesday’s decline was year-end positioning or the start of a broader rotation away from big tech.

Stock Market Today

  • US Stocks Surge on Hopes for Global Crude Supply Deal
    June 11, 2026, 5:34 PM EDT. U.S. stocks surged to their best day in two months on Thursday following President Donald Trump's decision to call off a threat to bomb Iran, easing geopolitical tensions. The move sparked optimism for a potential deal to resume global crude oil flows, leading to a drop in oil prices. Investors welcomed reduced risk, boosting equities across major indexes. This development underscores the market's sensitivity to geopolitical risks and the vital role of crude oil supply stability in driving market sentiment.

Latest articles

Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

11 June 2026
Bank of Nova Scotia surged to a 52-week high, closing up 1.24% at C$115.27 in Toronto after announcing expanded AI adoption across its workforce and higher Q2 earnings, while the S&P/TSX Composite jumped 1.5% as financials rallied and trading volume soared above average.
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

11 June 2026
Moderna surged 7.94% to $49.64 as U.S. stocks rebounded sharply, with investors eyeing its mRNA cancer-vaccine pipeline after a UK trial authorization; Wall Street’s average analyst rating remains “Hold” with a $43.30 target, and BofA raised its price target to $34 citing norovirus prospects, while Moderna reported Q1 revenue of $389 million and a $1.3 billion net loss.
B2Gold shares move up as gold helps lift TSX miners

B2Gold shares move up as gold helps lift TSX miners

11 June 2026
B2Gold shares soared over 5% on both NYSE American and TSX as gold prices rebounded and investors piled into Canadian mining stocks, with the company’s strong sensitivity to bullion prices and recent leadership change fueling the rally; trading volume topped 32 million shares and B2Gold outperformed the TSX index.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop